ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,629 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryAnièresIREMIS Therapeutics SA
IREMIS Therapeutics SA Logo
Verified· 2 sourcesTrust Score
Summary

About the company

IREMIS Therapeutics SA develops therapeutic and theranostic solutions for neuropathic and other chronic pain conditions using a personalized medicine approach. The company is advancing its lead molecule IRX-001 (NDMC) in Phase II clinical development and applies pharmacogenetics, evidence‑based dosing guidance and patient monitoring to optimize treatment.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
3.8/5

IREMIS Therapeutics SA

✓ Offered4
Development of therapeutic solutions for chronic pain
Therapeutic and theranostic solutions for the treatment of neuropathic pain and other chronic pain conditions, with personalised medicine, dose adjustment and pharmacogenetic application.
Clinical development of IRX-001 (NDMC)
Clinical development of the lead compound IRX-001 (NDMC) for neuropathic pain, including Phase I and Phase IIa studies, as well as efficacy and tolerability data.
Research on GABA-A receptor modulation
Research into differential allosteric modulation of the GABA-A receptor, focusing on α2-mediated pain inhibition and avoiding sedative effects.
Preclinical pain research
Preclinical models and data on central sensitisation and neuropathic pain, including dose-dependent antihyperalgesic effects and a safety profile.
Trust & reputation

ranQ Trust Score of IREMIS Therapeutics SA: 3.8 out of 5.0

Trust Score3.8/ 5.0

High

x

Data basis 54% · As of October 2026

IREMIS Therapeutics SA has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
IREMIS Therapeutics SA scores 59.7 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.39.612%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.55.07%
IREMIS Therapeutics SA scores 83.3 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).83.322%
IREMIS Therapeutics SA scores 6.0 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.6.04%
  • Media authority: No data point — the criterion is taken out of the weighting and does not lower the score.—4%
Qualifications+0.00

IREMIS Therapeutics SA reaches a ranQ Trust Score of 3.8 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 54%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Knowledge

No knowledge articles yet

Once IREMIS Therapeutics SA has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

IREMIS Therapeutics SA in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank IREMIS Therapeutics SA by reviews, experience and specialisations.

Is this your company?

Claim the company profile of IREMIS Therapeutics SA to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Route d'Hermance 320
1247 Anières

At a glance

Legal form
Corporation
UID
CHE-386.085.813
Founded
2024 · 2 years
Last commercial register change
September 19, 2024
Employees
1 to 10
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    AT
    Atopia Therapeutics SA
    Geneva
    SS
    STALICLA SA
    Geneva
    CH
    Corsano Health SA
    Plan-Les-Ouates
    MT
    MPC Therapeutics SA
    Geneva
    AS
    argenx Switzerland SA
    Châtelaine
    SG
    SANOFI GESTION SA
    Vernier
    CR
    CELL RECEPTOR SA
    Geneva
    MM
    MMV MEDICINES FOR MALARIA VENTURE
    Cointrin